Beatrice Conca

Beatrice Conca

Auto-generated profile, based on publicly available information

Beatrice Conca

Università degli Studi di Milano Academic Centre for Research on Adenomyosis and Endometriosis, Department of Clinical Sciences and Community Health Milan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
VEVictoria Ettorre
Victoria Ettorre
BCBeatrice Conca
Beatrice Conca
CDCem Demirkiran
Cem Demirkiran
SBStefania Bellone
Stefania Bellone
NSNamrata Sethi
Namrata Sethi
ASAlessandro Santin
Alessandro Santin

21 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PVPaolo Pietro Vercellini
Paolo Pietro Vercellini
Noemi SalmeriNoemi Salmeri
Noemi Salmeri
VBVeronica Bandini
Veronica Bandini
BCBeatrice Conca
Beatrice Conca
Paola Vigano'Paola Vigano'
Paola Vigano'
MVMICHELE ANTONIO MARIA VIGNALI
MICHELE ANTONIO MARIA VIGNALI
Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, physicians’ clinical expertise, and the values and priorities of individual patients. In this non-systematic, comprehensive narrative review, data from available randomized controlled trials and meta-analyses on hormonal treatment for symptomatic endometriosis are interpreted through the lens of clinical experience. The role of patients in defining therapeutic trade-off balances is also taken into consideration. Most symptomatic patients benefit from hormonal therapy, including first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications, to relieve nociceptive pain. To reduce the risk of venous and arterial thrombosis and avoid stimulating lesions, it is preferable to use combinations containing body-identical estrogens rather than ethinyl-estradiol. The main adverse effect of first-line medications is irregular bleeding, which adversely impacts efficacy, tolerability, and adherence. If progestogens and estrogen-progestogens do not improve health-related quality of life (HRQoL), promptly stepping up to GnRH analogues combined with add-back therapy is indicated. Add-on rather than upfront combination therapy is suggested. Separating the analogues and add-back therapy allows for choosing the compounds that best suit the characteristics of individual patients. Transdermal body-identical estradiol use is proposed in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. Evidence on the use of neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from studies of other chronic pain conditions and shows limited effectiveness. The two mainstays of hormonal therapy are (i) ovariostasis and (ii) amenorrhea. “Medical treatment failure” should not be declared unless a shift from first-line to second-line medications has been undertaken whenever these conditions are not met. For severely symptomatic adolescents and young women, secondary prevention through ovariostasis and amenorrhea should be pursued promptly to improve HRQoL, halt lesion progression, and preserve reproductive potential.


4 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PVPaolo Pietro Vercellini
Paolo Pietro Vercellini
Noemi SalmeriNoemi Salmeri
Noemi Salmeri
VBVeronica Bandini
Veronica Bandini
BCBeatrice Conca
Beatrice Conca
Paola Vigano'Paola Vigano'
Paola Vigano'
MVMICHELE ANTONIO MARIA VIGNALI
MICHELE ANTONIO MARIA VIGNALI
Endometriosis is associated with nociceptive pain and with peripheral as well as central sensitization. To relieve nociceptive pain, most symptomatic patients benefits from hormonal therapy, which includes first-line (progestogens and estrogen-progestogen combinations) and second-line (GnRH agonists and antagonists) medications. To reduce venous and arterial thrombotic risk and avoid lesion stimulation, combinations containing bioidentical estrogens should be preferred to those containing ethinyl-estradiol. Irregular bleeding is the main adverse effect of first-line medications, adversely impacting efficacy, tolerability, and adherence. When progestogens and estrogen-progestogens do not improve the quality of life, prompt stepping up to GnRH analogues combined with add-back therapy is indicated. An add-on rather than upfront combination therapy is suggested. Keeping analogues and add-back therapy separate allows for the choice of the compounds that best suit individual patients’ characteristics. The transdermal use of bioidentical estradiol is suggested in combination with both progestogens and GnRH analogues. Similar satisfactory outcomes are achieved with GnRH agonists and antagonists. The evidence on neuromodulatory drugs to treat neuropathic and nociplastic pain is derived from other chronic pain conditions, and it demonstrates a limited effect. The two mainstays of hormonal therapy are i) ovariostasis and ii) amenorrhea. Whenever these are not obtained, and a shift from first-line to second-line medications has not been undertaken, “medical treatment failure” must not be declared. In severely symptomatic adolescents and young women, secondary prevention via ovariostasis and amenorrhea should be promptly pursued to improve quality of life, halt lesion progression, and preserve the reproductive potential.

19 October 2026 in Human Reproduction Open
Verified
Journal Article
Open access
PVPaolo Vercellini
Paolo Vercellini
BCBeatrice Conca
Beatrice Conca
Noemi SalmeriNoemi Salmeri
Noemi Salmeri
VBVeronica Bandini
Veronica Bandini
MVMICHELE ANTONIO MARIA VIGNALI
MICHELE ANTONIO MARIA VIGNALI